Clinical Trial Update: REGN3918 in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) to Evaluate Its Long Term Safety, Efficacy and Tolerability. [Phase 3]

View source ↗

Summary

This Phase 3 trial update for REGN3918 in paroxysmal nocturnal hemoglobinuria (PNH) was terminated, with results posted in 2023.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Paroxysmal Nocturnal Hemoglobinuria

Drugs mentioned

• REGN3918

Snippet

Sponsor: Regeneron Pharmaceuticals | Conditions: Paroxysmal Nocturnal Hemoglobinuria | Phase 3 | Status: TERMINATED | Results posted: 2023-06-12